StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Pfizer (PFE) Conducting Review of U.S. Treasury Notice, Won't Speculate on Potential Effect - Bloomberg, Citing Spokeswoman
April 4, 2016 5:53 PM
Pfizer (NYSE: PFE) Conducting ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Litigation
Management Comments
Mergers and Acquisitions
Trader Talk
Next Articles
BMO Capital Reiterates Outperform on Pfizer (PFE) Following Allergan Merger Termination
April 6, 2016 10:42 AM
Leerink Partners Cuts Price Target on Allergan (AGN) Following New U.S. Treasury Regulations
April 6, 2016 7:13 AM
Allergen's (AGN) Stand-Alone Price Target is $282 at Deutsche Bank
April 5, 2016 3:45 PM
Buy Allergen (AGN) at $220 Regardless of Deal Outcome - Leerink
April 5, 2016 8:54 AM
Treasury Action More than a Wrinkle for Pfizer (PFE)/Allergan (AGN) Deal - Jefferies
April 5, 2016 7:19 AM
New Treasury Action Could Block, or Significantly Change Pfizer (PFE)/Allergan (AGN) Deal - BMO Capital
April 5, 2016 6:53 AM
Allergen (AGN) Trading Below Standalone Value Following New Treasury Action - RBC
April 5, 2016 6:42 AM
Allergan (AGN), Pfizer (PFE) Comment on U.S. Treasury Action; Won't Comment on Potential Impact
April 5, 2016 6:37 AM
Allergan (AGN) Slammed on New U.S. Treasury Inversion Action; Pfizer (PFE) Higher
April 4, 2016 5:24 PM
U.S. Treasury Announces Latest Action to Limit Corporate Inversions
April 4, 2016 5:04 PM
U.S. Treasury, IRS issue more curbs to corporate tax inversion deals
April 4, 2016 5:01 PM
